AIG heads into the first week of September with options traders markedly more cautious than they have been all year, even as short sellers remain an afterthought in the stock's story.
The sharpest signal right now is in options positioning. The put/call ratio has climbed to 1.37 — nearly 1.6 standard deviations above its 20-day average of 1.14 — and is pressing toward its 52-week high of 1.42. That shift has happened fast: as recently as mid-August, the PCR was sitting just above 1.0, a neutral read. The move higher over the past two weeks points to meaningful demand for downside protection, with the next earnings date — November 4 — providing a plausible focal point. The last print, on August 7, sent the stock down roughly 3% on the day and a further 4% over the following week. The one before that dropped around 1.7% the day after and 5% over five days. Neither reaction was catastrophic, but the pattern of post-earnings softness is consistent enough to explain why put buyers are getting active now.
Short interest tells a far less dramatic story, and it would be wrong to make it the headline here. AIG's SI is just 1.45% of free float — low by any standard. It rose about 6% on the week in share count terms, unwinding some of the sharp 17% monthly decline that preceded it, but with over 521 million shares available to borrow, borrow availability is essentially unconstrained. Cost to borrow is 0.40%, near the bottom of its 30-day range. There is no meaningful squeeze setup, no borrow scarcity, and no conviction short position building. This is a stock where the bears express themselves through puts, not through the lending market.
The Street is broadly constructive but has been quietly trimming ambitions since the Q2 print. Several firms lowered targets in the August 10-17 window — Cantor Fitzgerald, Morgan Stanley, Mizuho, and Wells Fargo all pulled targets down while keeping ratings unchanged, a pattern that suggests analysts believe in the long-run thesis but are absorbing a weaker near-term delivery. Not everyone moved in that direction: Keefe Bruyette raised its target to $96 and RBC lifted to $87. The net result is a consensus mean target of $88.50, implying around 17% upside from AIG's current $75.88. Argus Research reiterated its Buy with a $90 target as recently as today. Valuation offers modest support — the stock trades below book value at 0.91x P/B, and the P/E is roughly 9x, both levels that keep the Value pillar constructive in ORTEX's factor framework. The short score of 29.9 sits at the 75th percentile, more a reflection of the stock's low float-on-loan characteristics than any directional conviction.
The bull case rests on improving P&C underwriting quality, 13% year-on-year growth in net investment income, and the Convex business compounding gross written premiums at 25% annually over three years. Bears point to persistent underwriting margin pressure from Convex and the EG acquisition, Global Personal Lines profitability struggles, and a buyback pace that has disappointed against the pace investors expected when AIG first set out its restructuring roadmap. Those competing narratives are reflected in the institutional register, which is passive-heavy: BlackRock holds 9.4% and Vanguard entities collectively own north of 12%, with no Schedule 13D activist on the register as of the most recent filings.
The pattern to watch into November is whether the PCR retreats back toward its 20-day average as summer positioning unwinds, or whether it continues pressing toward its 52-week high — and whether the Street's split between target-cutters and target-raisers resolves in one direction after the next quarterly update.
See the live data behind this article on ORTEX.
Open AIG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
